NewLink Genetics, Inc. (NLNK)

Oncology Corporate Profile

Stock Performance

20.3900
0.0000

HQ Location

2503 South Loop Drive, Suite 5100
Ames, IA 50010

Company Description

"NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens."

Website: http://newlinkgenetics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Algenpantucel-LimmunotherapyPancreatic cancerIII
indoximodIDO pathway inhibitorBrain MetastasesII
indoximodIDO pathway inhibitorBreast cancerII
Dorgenmeltucel-LimmunotherapyMelanomaII
Tergenpumatucel-LimmunotherapyNon Small Cell Lung Cancer (NSCLC)II
indoximodIDO pathway inhibitorProstate cancerII
HyperAcute_ ProstateimmunotherapyProstate cancerI
HyperAcute_ RenalimmunotherapyRenal cell carcinoma (RCC)I
NL G919IDO pathway inhibitorVarious cancer typesI

View additional information on product candidates here »

Source


http://newlinkgenetics.com

Recent News Headlines

Blog Coverage PTC Therapeutics Acquires Rights for Duchenne Muscular Dystrophy Drug from Marathon for $140 Million Upfront

3/17/2017 12:01 pm

[Accesswire] - Upcoming AWS Coverage on NewLink Genetics Post-Earnings Results LONDON, UK / ACCESSWIRE / March 17, 2017 / Active Wall St. blog coverage looks at the headline from PTC Therapeutics, Inc. (NASDAQ: PTCT ...

NewLink Genetics Announces Presentation of Two Abstracts at AACR

3/1/2017 10:00 pm

[GlobeNewswire] - AMES, Iowa, March 01, 2017-- NewLink Genetics Corporation, a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported that two abstracts on ...

NewLink reports 4Q loss

2/28/2017 01:04 pm

NewLink reports 4Q loss

2/28/2017 01:04 pm

NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results

2/28/2017 01:00 pm

[GlobeNewswire] - AMES, Iowa, Feb. 28, 2017-- NewLink Genetics Corporation, a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported consolidated financial ...

NewLink Genetics to Host Its Fourth Quarter and Year End 2016 Financial Results Conference Call on February 28, 2017

2/20/2017 12:00 pm

[GlobeNewswire] - AMES, Iowa, Feb. 20, 2017-- NewLink Genetics Corporation, today reported that it will release its fourth quarter and year end 2016 financial results on Tuesday, February 28, 2017. The company has scheduled ...

NewLink Genetics to Participate in 2017 SunTrust Orphan Drug Day on February 14th

2/13/2017 12:00 pm

[GlobeNewswire] - AMES, Iowa, Feb. 13, 2017-- NewLink Genetics Corporation, a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today announced that it will participate ...

Lifshitz & Miller Law Firm Announces Investigation of DaVita Inc., First NBC Bank Holdings Company, Fresenius Medical Care AG & Co. KGAA, Inotek Pharmaceuticals Corporation, Natural Health Trends Corp., NeoPhotonics Corporation, NewLink Gen

1/18/2017 08:04 pm

[PR Newswire] - NEW YORK, Jan. 18, 2017 /PRNewswire/ -- DaVita Inc. (DVA) Lifshitz & Miller announces investigation on behalf of DVA investors concerning the receipt of subpoenas from federal prosecutors seeking "information ...

Newman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation

1/9/2017 09:04 pm

[Business Wire] - Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation into potential breaches of fiduciary duty by the Company’s Board of Directors .